RxDoctor Payments Data

Alden Haun, MD

Ophthalmology · Maryville, TNNPI 1316941842

Payments from drug & device makers

$3,832in general payments, 2019–2025

Across 122 payments — averaging $31.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$458
  • Bausch & Lomb Americas Inc.$336
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$335
  • Johnson & Johnson Surgical Vision, Inc.$325
  • Optos, Inc.$218
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,67796%
  • Gifts$170%
  • Entertainment$1374%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,832 in reported general payments places this provider in the 70th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$498,906
Medicare patients
1,790
Services billed
4,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine82$93,590
LumiganBimatoprost52$28,545
IlevroNepafenac65$24,250
MieboPerfluorohexyloctane/Pf13$15,822
Prednisolone Acetate185$10,301
Travoprost46$8,494
Latanoprost526$6,426
Brimonidine Tartrate83$5,081
CombiganBrimonidine Tartrate/Timolol12$4,958
VyzultaLatanoprostene Bunod11$4,882
Timolol Maleate229$4,767
Alphagan PBrimonidine Tartrate11$4,041
Bromfenac Sodium13$1,918
MoxifloxacinMoxifloxacin Hcl64$1,790
Fluorometholone21$1,503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$458$131,135157 claims
NovartisIlevro$57$24,25065 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$336$20,70424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Maryville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →